+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
CONCORDBIO

Concord Biotech Share Price

₹1,414.60 -6.2 (-0.44%)
43.32% Gain from 52W Low

03 Aug, 2026 3:56 PM (IST)

Concord Biotech live price: ₹1,414.60. It opened at ₹1,444 vs previous close ₹1,421; intraday high/low: ₹1,456/₹1,389. The 50 & 200 DMA stand at ₹1,279.10/₹1,310.00.

Concord Biotech Performance

  • Today's Low
  • ₹1,389
  • Today's High
  • ₹1,456
  • 52 Week Low
  • ₹987
  • 52 Week High
  • ₹1,802
  • Open Price₹1,444
  • Previous Close₹1,421
  • Volume431,423
  • 50 DMA₹1,279.10
  • 100 DMA₹1,255.50
  • 200 DMA₹1,310.00

Concord Biotech Chart

Investment Returns

  • Over 1 Month + 9.99%
  • Over 3 Month + 23.87%
  • Over 6 Month + 27.56%
  • Over 1 Year -18.73%

Smart Investing Starts Here Start SIP with Concord Biotech for Steady Growth!

Invest Now

Concord Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 53.7
  • PEG Ratio
  • -2.4
  • Market Cap Cr
  • 14,799
  • P/B Ratio
  • 7.3
  • Average True Range
  • 49.6
  • EPS
  • 26.3
  • Dividend Yield
  • 1.3
  • MACD Signal
  • 21.7
  • RSI
  • 67.32
  • MFI
  • 82.78

Latest Stock News Updates

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

The audio recording of the conference held on August 03, 2026 has been hosted on the website of the company and link to access the said recording is as follows: - Link : https://concordbiotech.com/wp-content/uploads/2026/08/Concord-Biotech-Q1-FY27-Earnings-Call-Audio-Recording.mp3

Concord Biotech Results Earnings Call for Q1FY27

Conference Call with Concord Biotech Management and Analysts on Q1FY27 Performance and Outlook. Listen to the <a href="https://youtu.be/M-PVtjmZNRo">full earnings transcript</a>. <br>

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Investor Presentation

Investors'' Presentation on unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026

Concord Biotech Financials

Concord Biotech Technicals

EMA & SMA

Current Price
₹1,414.60
-6.2 (-0.44%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹1,319.60
  • 50 Day
  • ₹1,279.10
  • 100 Day
  • ₹1,255.50
  • 200 Day
  • ₹1,310.00

Resistance and Support

1419.97 Pivot Speed
  • R3 1,518.20
  • R2 1,487.30
  • R1 1,450.90
  • S1 1,383.60
  • S2 1,352.70
  • S3 1,316.30

Concord Biotech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-31 Quarterly Results
2026-05-29 Audited Results & Final Dividend
2026-02-11 Quarterly Results
2025-11-13 Quarterly Results
2025-08-08 Quarterly Results
Date Purpose Remarks
2026-07-24 FINAL Rs.7.55 per share(755%)Final Dividend
2025-09-03 FINAL Rs.10.70 per share(1070%)Final Dividend
2024-06-22 FINAL Rs.8.75 per share(875%)Dividend
View Concord Biotech Dividend History Arrow

Concord Biotech Shareholding Pattern

44.08%
39.04%
7.53%
4.97%
4.4%

About Concord Biotech

Concord Biotech Ltd. is leading biotechnology company in India, specializing in development & manufacturing of fermentation based biopharmaceuticals. Established in 2000, company has grown to become significant player in global biotech industry, with strong focus on immunosuppressants, oncology, & nephrology products. Concord Biotech's state of the art manufacturing facilities are designed to meet international quality standards, enabling company to supply its products to over 70 countries worldwide. company's dedication to innovation, research, & development has made it trusted partner in global healthcare industry.

diversified clientele: 200 clients in more than 70 countries use company's API & formulation solutions. long-term supply agreements with these clients accounted for 14.06%, 12.45%, & 12.56% of their revenues in FY21, FY22, & FY23.
R&D: Concord maintains specialized R&D facilities for formulations & APIs in Dholka & Valthera. Both have Indian DSIR's approval. Their R&D units employed 148 people as of March 31, 2022, making up 11.99% of their total number of permanent employees.

Domestic Presence: They sell range of 27 products in India, including immunosuppressants, nephrology medications, & anti-infective medications used in critical care. In India, they are present in 20 states & 5 union territories.

View More
  • NSE Symbol
  • CONCORDBIO
  • BSE Symbol
  • 543960
  • Executive Director,Joint Managing Director,Chief Executive Officer
  • ANKUR VAID
  • ISIN
  • INE338H01029

Similar Stocks to Concord Biotech

Concord Biotech FAQs

Concord Biotech share price is ₹1,414 As on 03 August, 2026 | 23:49

The Market Cap of Concord Biotech is ₹14799 Cr As on 03 August, 2026 | 23:49

The P/E ratio of Concord Biotech is 53.7 As on 03 August, 2026 | 23:49

The PB ratio of Concord Biotech is 7.3 As on 03 August, 2026 | 23:49

The 52 week High & Low of Concord Biotech is ₹1801.9/₹987 respectively As on 03 August, 2026 | 23:49

Consider company's product pipeline & growth prospects in biotech industry before investing.
 

Key metrics include revenue from key therapeutic areas, R&D investment, & profit margins.

Open Demat account with 5 Paisa Capital & post doing KYC & active account search for Concord Biotech share, you can then put order as you prefer.

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23